found
antihuman
antibodi
crossreact
canin
lymphocyt
block
alloimmun
respons
vitro
base
pharmacokinet
studi
dog
receiv
singl
intraven
inject
mgkg
antibodi
day
follow
day
later
donor
pbmc
day
dog
given
gy
tbi
underw
dlaident
marrow
graft
postgraft
immunosuppress
consist
mmf
csp
dog
demonstr
initi
engraft
dog
sustain
engraft
week
wherea
dog
reject
graft
week
surviv
autolog
recoveri
graft
surviv
significantli
improv
histor
control
condit
tbi
given
either
mmf
rapamycin
csp
hct
reject
graft
week
p
preced
donor
pbmc
infus
blockad
improv
surviv
dlaident
marrow
graft
tbi
sustain
engraft
dog
leukocyt
antigen
dla
ident
litterm
marrow
rule
dog
condit
nonmyeloabl
dose
gy
total
bodi
irradi
tbi
given
short
cours
postgraft
immunosuppress
either
mycophenol
mofetil
mmf
rapamycin
along
cyclosporin
csp
howev
uniform
graft
reject
seen
tbi
condit
decreas
gy
contrast
dog
show
sustain
engraft
tbi
preced
intraven
inject
peripher
blood
mononuclear
cell
pbmc
marrow
donor
tcell
costimulatori
blocker
use
tbi
condit
evalu
whether
blockad
anoth
costimulatori
pathwayth
interact
equal
effect
enhanc
marrow
engraft
blockad
pathway
success
murin
model
hematopoiet
stem
cell
transplant
differ
anim
model
solid
organ
transplant
litter
beagl
minimongrel
basenji
golden
retriev
crossbre
either
rais
fred
hutchinson
cancer
research
center
fhcrc
purchas
commerci
kennel
assess
diseas
enrol
veterinari
prevent
medicin
program
worm
distemp
parvoviru
adenoviru
type
parainfluenza
viru
corona
viru
rabi
canin
papillomaviru
dog
age
month
weigh
kg
median
kg
studi
approv
fhcrc
institut
anim
care
use
committe
accredit
associ
assess
accredit
laboratori
anim
care
intern
dlaident
litterm
select
donorrecipi
pair
basi
match
highli
polymorph
microsatellit
marker
within
dla
class
class
ii
region
confirm
sequenc
hybridoma
cell
line
obtain
american
type
cultur
collect
manassa
va
produc
mous
antihuman
monoclon
antibodi
mab
hybridoma
cell
cultiv
accord
guidelin
provid
mab
purifi
supernat
check
endotoxin
fhcrc
biolog
product
facil
endotoxinfre
antibodi
dilut
phosphatebuff
salin
pb
without
calcium
magnesium
concentr
mgml
immedi
frozen
use
crossreact
mab
determin
flow
cytometri
use
canin
lymphocyt
stimul
pma
ionomycin
studi
canin
pbmc
separ
ml
blood
use
ficol
gradient
centrifug
specif
densiti
gdl
cell
wash
count
resuspend
rpmi
medium
supplement
heatinactiv
canin
serum
mmol
lglutamin
uml
penicillin
gml
streptomycin
mol
concentr
cell
per
ml
cell
suspens
sampl
plate
plate
sampl
per
plate
ionomycin
pma
ad
lymphocyt
cultur
final
concentr
gml
respect
medium
supplement
obtain
gibco
invitrogen
carlsbad
ca
sigmaaldrich
st
loui
mo
pbmc
cultiv
hour
harvest
wash
resuspend
pb
goat
serum
sodium
azid
cell
count
concentr
adjust
ml
cell
centrifug
rpm
minut
remov
supernat
cell
resuspend
l
mab
solut
concentr
gml
incub
ice
minut
wash
ml
pb
goat
serum
sodium
azid
centrifug
supernat
remov
cell
resuspend
fluorescein
isothiocyan
fitc
label
goat
antimous
secondari
antibodi
solut
dilut
jackson
immunoresearch
laboratori
west
grove
pa
incub
dark
minut
wash
resuspend
ml
pb
goat
serum
sodium
azid
cell
analyz
use
facscalibur
machin
cell
quest
pro
softwar
becton
dickinson
franklin
lake
nj
correspond
isotyp
control
obtain
dako
north
america
carpinteria
ca
mix
leukocyt
reaction
mlr
perform
describ
previous
purifi
mab
ad
medium
concentr
gml
initi
test
dose
increas
gml
gml
determin
dose
effect
courtesi
dr
richard
boismenu
repligen
corp
waltham
use
posit
control
irrelev
mous
antibodi
use
neg
control
three
dog
receiv
singl
intraven
iv
dose
mab
mgkg
dog
previous
expos
mous
immunoglobulin
inject
serial
blood
sampl
obtain
minut
hour
day
blood
centrifug
serum
immedi
store
serum
concentr
mab
measur
enzymelink
immunosorb
assay
elisa
briefli
antimous
iggpreco
plate
r
biosystem
minneapoli
mn
block
chicken
serum
tween
contain
pb
incub
canin
serum
treat
dog
dilut
sampledepend
bound
detect
horseradish
peroxidaseconjug
goat
antimous
igg
pierc
rockford
il
secondari
antibodi
color
reagent
acid
sigma
plate
read
vmax
microtit
plate
reader
molecular
devic
menlo
park
ca
nm
standard
curv
establish
known
concentr
sera
obtain
dog
mab
infus
serv
control
similar
procedur
use
detect
canin
antibodi
except
plate
coat
dlaident
marrow
transplant
dog
solut
bound
antibodi
detect
horseradish
peroxidaseconjug
goat
antidog
igm
chain
goat
antidog
igg
chain
immunolog
consult
laboratori
newberg
distinguish
isotyp
activ
pool
normal
dog
serum
serv
neg
control
canin
serum
sampl
dilut
day
marrow
transplant
recipi
given
mgkg
ketorolac
iv
prophylaxi
thrombosi
describ
treatment
day
anim
receiv
mgkg
iv
day
donor
pbmcskg
administ
half
cell
infus
iv
half
given
subcutan
optim
antigen
present
day
recipi
given
tbi
donor
marrow
describ
previous
marrow
graft
contain
nucleat
cell
nc
kg
median
ncskg
compar
cell
dose
use
previou
studi
median
total
ncskg
studi
csp
mmf
ncskg
studi
csp
sirolimu
dog
receiv
standard
posttransplant
care
immunosuppress
consist
csp
mgkg
twice
day
oral
day
day
mmf
mgkg
twice
day
subcutan
day
day
csp
level
measur
weekli
result
use
csp
dose
adjust
mmf
dose
adjust
accord
clinic
toxic
mainli
gastrointestin
hematopoiet
engraft
assess
document
donor
dinucleotid
tetranucleotid
variablenumb
tandem
repeat
vntr
polymorph
granulocyt
mononuclear
cell
peripher
blood
use
polymeras
chain
reaction
pcr
base
assay
describ
previous
sampl
drawn
weekli
first
week
everi
week
thereaft
month
posttransplant
pcr
product
analyz
gel
electrophoresi
percentag
donor
chimer
recipi
determin
use
imagequ
softwar
ampl
softwar
pti
ltd
turramurra
nsw
australia
autoradiographi
day
weekli
first
week
posttransplant
serum
sampl
obtain
determin
mab
serum
concentr
dog
immun
respons
antibodi
respons
treat
mlr
cultur
control
compar
use
pair
student
test
durat
engraft
among
current
dog
compar
histor
control
tabl
use
logrank
test
associ
among
transplant
marrow
cell
dose
donor
chimer
level
week
durat
donor
chimer
evalu
use
spearman
rank
correl
coeffici
report
p
valu
consid
signific
figur
illustr
crossreact
mab
activ
canin
lymphocyt
compar
murin
isotyp
control
antibodi
flow
cytometri
result
indic
nearli
log
increas
intens
bind
mab
neg
control
mlr
studi
use
cell
dlamismatch
dog
addit
irrelev
antibodi
mab
concentr
gml
medium
figur
mab
reduc
hthymidin
uptak
compar
medium
alon
p
reduc
mlr
respons
p
differ
mlr
reactiv
condit
consist
either
gy
tbi
posttransplant
immunosuppress
csp
combin
mmf
sirolimu
srl
p
valu
refer
comparison
current
result
previou
studi
use
logrank
test
mab
signific
p
increas
mab
concentr
beyond
gml
decreas
hthymidin
uptak
wherea
gml
mab
also
led
signific
mlr
suppress
p
data
shown
concentr
gml
significantli
decreas
hthymidin
uptak
ten
minut
inject
mab
serum
concentr
reach
maximum
level
gml
dog
mgkg
dose
gml
dog
mgkg
dose
gml
dog
mgkg
dose
figur
serum
level
declin
rapidli
within
hour
gml
gml
gml
respect
like
reflect
distribut
antibodi
serum
level
continu
declin
gradual
ensu
day
follow
rapid
clear
mab
day
side
effect
mab
inject
seen
antimab
antibodi
began
appear
day
inject
titer
increas
mab
clear
circul
figur
immun
respons
predominantli
igg
isotyp
lesser
contribut
igm
antibodi
parallel
elisa
test
mab
mous
plate
suggest
anim
either
pure
dog
predominantli
dog
antiidiotyp
iggrespons
wherea
anim
antimous
isotyp
respons
dog
recipi
dog
characterist
outcom
hct
summar
tabl
figur
summar
dog
serum
concentr
mab
canin
antibodi
respons
mab
former
rang
gml
median
gml
day
gml
mab
irrelev
mab
neg
control
posit
control
ad
concentr
gml
maximum
hthymidin
uptak
medium
control
experi
set
error
bar
repres
standard
deviat
p
valu
calcul
use
pair
student
test
medium
versu
irrelev
mab
p
medium
versu
p
medium
versu
p
mab
versu
p
dian
gml
day
antibodi
clearanc
consider
slower
seen
pharmacokinet
studi
day
four
dog
develop
igg
antibodi
dog
antibodi
detect
day
transplant
second
peak
occur
cessat
postgraft
immunosuppress
dog
antimab
antibodi
appear
beyond
day
correl
antibodi
respons
durat
hematopoiet
engraft
seen
dog
exhibit
prompt
initi
marrow
engraft
neutrophil
platelet
count
show
nadir
around
day
hct
eventu
blood
count
recoveri
occur
figur
lymphocyt
count
remain
day
recov
peak
donor
chimer
level
median
granulocyt
week
figur
tabl
median
mononuclear
cell
week
figur
tabl
three
dog
demonstr
graft
reject
week
respect
remain
stabl
respect
mix
donorhost
chimera
week
followup
median
durat
engraft
dog
significantli
greater
histor
control
given
pretransplant
treatment
p
logrank
test
tabl
figur
shorter
achiev
tbi
statist
signific
differ
current
result
regimen
use
treatment
tbi
antithymocyt
globulin
donor
pbmc
methotrex
donor
pbmc
tabl
cumul
rate
engraft
significantli
higher
rate
histor
control
receiv
pretransplant
treatment
p
fisher
exact
test
tabl
high
granulocyt
chimer
level
week
correl
significantli
sustain
en
hematolog
nonhematolog
toxic
mild
compar
seen
previou
studi
use
tbi
postgraft
mmf
csp
first
dog
show
allerg
reaction
mab
infus
resolv
diphenylhydramin
hydrat
therefor
subsequ
dog
receiv
diphenylhydramin
mgkg
iv
minut
mab
infus
prophylaxi
allerg
reaction
one
dog
develop
intussuscept
like
relat
csp
requir
surgic
correct
suspens
postgraft
immunosuppress
hour
gvhd
observ
dog
current
studi
demonstr
pretreat
recipi
mab
donor
pbmc
led
prolong
engraft
dlaident
marrow
dog
condit
tbi
treat
short
cours
mmf
csp
transplant
howev
sustain
engraft
seen
half
recipi
result
similar
seen
studi
mice
uniform
engraft
depend
strain
combin
use
total
marrow
cell
dose
inject
dose
marrow
cell
cellskg
result
engraft
even
resist
mous
strain
combin
wherea
inject
marrow
cell
led
chimer
mice
compar
marrow
cell
dose
could
achiev
dog
note
dog
highest
marrow
cell
dose
cellskg
among
dog
exhibit
stabl
engraft
week
previou
studi
marrow
transplant
mice
solid
organ
transplant
nonhuman
primat
use
higher
total
dose
mab
administ
current
studi
limit
pharmacokinet
data
mab
report
literatur
two
studi
examin
pharmacokinet
human
mab
monkey
antibodi
respons
control
dog
receiv
pretransplant
treatment
dog
condit
tbi
receiv
marrow
graft
dlaident
litterm
given
mmf
rapamycin
day
csp
day
posttransplant
mab
detect
primat
studi
suppress
tcelldepend
bcell
respons
solubl
antigen
tetanu
toxoid
ovalbumin
use
determin
vivo
efficaci
antibodi
studi
singl
dose
mab
effect
suppress
antibodi
respons
foreign
antigen
although
human
mab
result
complet
suppress
even
mab
dose
mgkg
present
studi
complet
mlr
suppress
observ
even
high
dose
mab
chose
smallest
antibodi
dose
vivo
studi
achiev
serum
antibodi
level
gml
least
day
realiz
singl
mab
dose
mgkg
iv
serum
concentr
mab
gml
even
day
inject
dog
pharmacokinet
studi
dog
transplant
studi
develop
igg
antibodi
respons
mab
begin
earli
day
inject
emerg
canin
antibodi
like
determin
tempo
clearanc
mab
circul
develop
igg
respons
without
preced
igm
respons
surpris
dog
known
previou
exposur
mous
immunoglobulin
dog
analyz
antiidiotyp
idiotypelik
antibodi
found
unlik
mice
dog
maintain
pathogenfre
condit
might
result
educ
immun
system
result
achiev
blockad
dog
significantli
differ
previous
seen
blockad
use
studi
fail
accomplish
uniform
sustain
engraft
given
increas
number
newli
discov
tcell
regulatori
costimulatori
molecul
seem
like
blockad
one
system
might
suffici
overcom
host
resist
lowintens
verylowintens
condit
regimen
perhap
combin
mab
might
synergist
addit
lead
uniform
sustain
engraft
describ
murin
model
marrow
islet
transplant
conclus
block
costimulatori
signal
feasibl
partial
success
establish
sustain
allogen
canin
marrow
graft
condit
tbi
caninespecif
molecul
combin
differ
costimulatori
blocker
may
requir
uniform
success
